Keith Rye’s Post

Are you self-funding and facing difficult coverage decisions for GLP-1 medications? You're not alone. Many organizations are grappling with the same challenges. Discover how other companies and institutions are navigating this pressing issue and finding innovative solutions by reading this article: https://lnkd.in/eHPJT455 #HealthCoverage #SelfFunding #GLP1 #HealthcareManagement #EmployeeHealth #CostSavings #ChronicCare #HealthInnovation

Are you self-funding and facing difficult coverage decisions for GLP-1 medications? You're not alone. Many organizations are grappling with the same challenges. Discover how other companies and institutions are navigating this pressing issue and finding innovative solutions by reading this article: https://lnkd.in/eADqbGev #HealthCoverage #SelfFunding #GLP1 #HealthcareManagement #EmployeeHealth #CostSavings #ChronicCare #HealthInnovation

The world of hospital #pharmacy is becoming #pharma. Check out this article from Pharmacy Purchasing & Products. Are hospitals ready to take on #drugmanufacturing? Share your thoughts below. #cgmp #healthcare #pharma #503b #fda #fdacompliance

Thoughts? Hospitals as #503bs, and producing #cellandgenetherapies? Are they ready for #cgmp? As an industry, have we left them no alternative or is this an evolution in how healthcare is delivered. Please comment below! https://lnkd.in/evpgQRMd #healthcare #hospitalpharmacy #fda #fdacompliance #cellandgenetherapy #cgt #503b

Today's a big day for compounding in California: Another what-is-likely-to-be epic California Board of Pharmacy hearing on its proposed sterile compounding regs. This radio interview (from yesterday) with patient Crystal Frost is a pretty good explanation of some of what's at stake. If you're licensed (or interested) in California, this audio is worth a listen: https://lnkd.in/eaXYw6FK #compounding #pharmacycompounding #sterilecompounding Alliance for Pharmacy Compounding

We're getting ready for Alliance for Pharmacy Compounding's Owner Summit! It's a fantastic chance to hear from Eagle’s President, Dr. Ross A. Caputo, PhD, who will be presenting on "The Economics of Quality." Be sure to swing by booth #26 to talk about how we can improve your compounding pharmacy practices. #eagleanalytical #compounding #compoundingpharmacy

Pulsed Field Ablation Innovator, Arga, has just raised €54 million in an oversubscribed financing round. The investors included Advent Life Sciences (UK), Earlybird Health (Germany), a new investor Gilde Healthcare (the Netherlands) as well as an undisclosed strategic investor. This start-up was founded by David Naele and Randy Werneth in 2020, to develop Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation. Supporting Argá Medtech SA since its formation, Kellerhals Carrard advised on the Swiss contractual aspects of this round and collaborated with Wilson Sonsini Goodrich & Rosati from the US side. The Kellerhals Carrard team was led by Jean-Luc Chenaux (pictured) (Partner, M&A), and further comprised Frédéric Rochat (Partner, M&A), François Kaiser (Partner, M&A), Serge Migy (Partner, Tax) Virginie A. Rodieux (Partner, IP) as well as Cindy Liu-Ung and Joséphine Marmy (Senior Associates, M&A) and Brian Jurt (Tax advisor). Read the article >> https://lnkd.in/dJe2u5Qu #Legalcommunitych #legaladvisor #financinground

📚 $3M surplus, $250k saved with manufacturer assistance, 93% savings on dialysis & more - all inside the new Case Study Collection. ➡️ Scroll now & download it for later: https://lnkd.in/eXc5NKuv Inside: 💥 How an auto dealer saved $6M leveraging a dialysis performance optimizer. 💥 The five-year, $3M surplus journey for a 600-employee life professional services group. 💥 30% savings on high-cost drugs with a better sourcing strategy. 💥 $250k savings with a Manufacturer Assistance Program for a growing technology group in the Southwest. #selffunding #healthcarecosts #insuranceadvisors

Impact Biomedical, Inc. Announces Pricing of Initial Public Offering    Today marks a significant milestone for Impact BioMedical Inc. (NYSE American: IBO) as we announce the pricing of our initial public offering of 1,500,000 shares at $3.00 per share. Starting today, September 16, 2024, our shares will begin trading on the NYSE American Market under the ticker symbol “IBO.”   The offering is expected to close on September 17, 2024, with an additional 45-day option for underwriters to purchase up to 225,000 more shares, further bolstering our public debut.   As we embark on this exciting chapter, Impact BioMedical remains committed to discovering and developing innovative solutions in human healthcare and wellness. This IPO is a testament to our vision and continued growth as we bring new offerings to market.   https://lnkd.in/eT79gSUK   #ImpactBioMedical #IPO #HealthcareInnovation #NYSE #LifeSciences #IBO Revere Securities

Impact Biomedical, Inc. Announces Pricing of Initial Public Offering    Today marks a significant milestone for Impact BioMedical Inc. (NYSE American: IBO) as we announce the pricing of our initial public offering of 1,500,000 shares at $3.00 per share. Starting today, September 16, 2024, our shares will begin trading on the NYSE American Market under the ticker symbol “IBO.”   The offering is expected to close on September 17, 2024, with an additional 45-day option for underwriters to purchase up to 225,000 more shares, further bolstering our public debut.   As we embark on this exciting chapter, Impact BioMedical remains committed to discovering and developing innovative solutions in human healthcare and wellness. This IPO is a testament to our vision and continued growth as we bring new offerings to market.   https://lnkd.in/eii5sHPN   #ImpactBioMedical #IPO #HealthcareInnovation #NYSE #LifeSciences #IBO Revere Securities